Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03989362
Title Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer (EMERGE)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Jounce Therapeutics, Inc.

lung non-small cell carcinoma

transitional cell carcinoma


Ipilimumab + Vopratelimab

Age Groups: senior | adult
Covered Countries USA | CAN

No variant requirements are available.